卡铂和紫杉醇用于治疗晚期或复发性子宫内膜癌。
Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
作者信息
Akram Tahira, Maseelall Priya, Fanning James
机构信息
Department of Obstetrics and Gynecology, Summa Health System, Northeastern Ohio Universities College of Medicine, Akron 44309, USA.
出版信息
Am J Obstet Gynecol. 2005 May;192(5):1365-7. doi: 10.1016/j.ajog.2004.12.032.
OBJECTIVE
The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer.
STUDY DESIGN
This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial adenocarcinoma that had been treated with outpatient carboplatin and taxol. Taxol was delivered at 135 mg/m 2 over 3 hours, and carboplatin was delivery at an area under the curve of 5 over 1 hour. Cycles were repeated every 21 days.
RESULTS
The overall response rate was 63% with 28% of patients who had a partial response and 35% of patients who had a complete response. Kaplan-Meier test was used to estimate the median survival time of 27 months and the median progression free survival time of 24 months. No patient had neutropenia, thrombocytopenia or grade 3 vomiting, neurosensory toxicity, or renal toxicity.
CONCLUSION
Carboplatin and taxol for the treatment of advanced or recurrent endometrial cancer appear to be active regimens with minimal toxicity.
目的
本研究旨在确定卡铂和紫杉醇在治疗晚期或复发性子宫内膜癌中的活性及毒性。
研究设计
这是一项对18例连续的晚期（4期）或复发性子宫内膜腺癌患者进行的回顾性研究，这些患者接受了门诊卡铂和紫杉醇治疗。紫杉醇以135mg/m²的剂量在3小时内输注，卡铂以曲线下面积为5的剂量在1小时内输注。每21天重复一个周期。
结果
总体缓解率为63%，其中28%的患者部分缓解，35%的患者完全缓解。采用Kaplan-Meier检验估计中位生存时间为27个月，中位无进展生存时间为24个月。没有患者出现中性粒细胞减少、血小板减少或3级呕吐、神经感觉毒性或肾毒性。
结论
卡铂和紫杉醇治疗晚期或复发性子宫内膜癌似乎是活性方案，毒性最小。
Zotero 插件